X

Trial Profile

A retrospective observational study: effectiveness of iGlarLixi in treating T2DM patients in clinical practice in Japan

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin-glargine/lixisenatide (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms SPARTA Japan
Sponsors Sanofi K.K.

Most Recent Events

12 Feb 2023 Results (n=337) of a sub-group analysis based on prior T2D treatment published in the Diabetes Therapy
23 Nov 2022 Results assessing the effect of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice published in the Diabetes Therapy
30 May 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com